טוען...
A phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): SWOG study S0329
BACKGROUND: A phase I study and an institutional pilot study in patients with metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN), utilizing biweekly gemcitabine-paclitaxel showed an overall response rate of 53%. This phase II trial was conducted to determine the feasibility, t...
שמור ב:
| הוצא לאור ב: | Head Neck |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4640463/ https://ncbi.nlm.nih.gov/pubmed/24166832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.23522 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|